Grandbrothers/iStock Editorial via Getty Images
Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX), as a treatment for plaque psoriasis, a skin-related autoimmune disease.
Specifically, the FDA has approved the